cocrystal (otcqb:cocp) is a pharmaceutical company seeking to discover novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. cocrystal employs unique technologies and nobel prize winning expertise to create first- and best-in-class antiviral drugs. these technologies, including our nucleoside chemistry expertise and market-focused approach to drug discovery are designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer. the company has identified promising, preclinical stage antiviral compounds for the unmet medical needs including hepatitis, influenza and norovirus infections. cocrystal has previously received strategic investments from teva pharmaceuticals, opko health (opk), dr. raymond schinazi, brace pharmaceutical, llc, and the frost group.
Company profile
Ticker
COCP
Exchange
Website
CEO
Gary Wilcox
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
BIOZONE PHARMACEUTICALS, INC., International Surf Resorts, Inc.
SEC CIK
Corporate docs
Subsidiaries
Cocrystal Discovery, Inc. • Cocrystal Merger Sub, Inc. ...
COCP stock data
Latest filings (excl ownership)
10-K/A
2023 FY
Annual report (amended)
17 Apr 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
28 Mar 24
8-K
Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A
19 Mar 24
8-K
Termination of a Material Definitive Agreement
1 Mar 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates
4 Jan 24
8-K
Termination of a Material Definitive Agreement
21 Dec 23
8-K
Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A
6 Dec 23
8-K
Regulation FD Disclosure
4 Dec 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 29.81 mm | 29.81 mm | 29.81 mm | 29.81 mm | 29.81 mm | 29.81 mm |
Cash burn (monthly) | 893.67 k | 1.03 mm | 1.48 mm | 1.53 mm | 893.67 k | 1.35 mm |
Cash used (since last report) | 6.11 mm | 7.01 mm | 10.12 mm | 10.47 mm | 6.11 mm | 9.24 mm |
Cash remaining | 23.71 mm | 22.80 mm | 19.69 mm | 19.34 mm | 23.71 mm | 20.57 mm |
Runway (months of cash) | 26.5 | 22.2 | 13.3 | 12.6 | 26.5 | 15.2 |
Institutional ownership, Q2 2023
55.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 21 |
Opened positions | 0 |
Closed positions | 2 |
Increased positions | 3 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 1.30 bn |
Total shares | 5.64 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
OPK Opko Health | 3.66 mm | $3.18 mm |
Phillip MD Frost Et Al | 1.32 mm | $2.71 mm |
Vanguard | 271.45 k | $648.75 mm |
Renaissance Technologies | 124.53 k | $298.00 k |
BLK Blackrock | 74.06 k | $177.01 mm |
Geode Capital Management | 69.53 k | $166.19 mm |
MS Morgan Stanley | 44.45 k | $106.24 mm |
STT State Street | 24.44 k | $58.42 mm |
Parallel Advisors | 15.23 k | $36.40 mm |
Susquehanna International | 14.90 k | $35.60 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Jul 23 | Kornberg Roger D. | Stock Options Common Stock | Grant | Acquire A | No | No | 2.67 | 24,417 | 65.19 k | 24,417 |
18 Jul 23 | Lee Sam | Stock Options Common Stock | Grant | Acquire A | No | No | 2.67 | 30,000 | 80.10 k | 30,000 |
18 Jul 23 | Pfenniger Richard C JR | Stock Options Common Stock | Grant | Acquire A | No | No | 2.67 | 7,333 | 19.58 k | 7,333 |
18 Jul 23 | Phillip MD Frost Et Al | Stock Options Common Stock | Grant | Acquire A | No | No | 2.67 | 19,333 | 51.62 k | 19,333 |
18 Jul 23 | Anthony J Japour | Stock Options Common Stock | Grant | Acquire A | No | No | 2.67 | 13,567 | 36.22 k | 13,567 |
News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
10 Apr 24
HC Wainwright & Co. Reiterates Buy on Cocrystal Pharma, Maintains $10 Price Target
4 Apr 24
Cocrystal Pharma Q4 EPS $(0.44) Beats $(0.60) Estimate
28 Mar 24
Recap: Cocrystal Pharma Q4 Earnings
28 Mar 24
Cocrystal Pharma Receives Pre-IND Responses From The FDA On Oral CC-42344 For Treating Influenza A
19 Mar 24